Transport of the Photodynamic Therapy Agent 5-Aminolevulinic Acid by Distinct H⁺-Coupled Nutrient Carriers Co-expressed in the Small Intestine

Catriona M.H. Anderson, Mark Jevons, Muthusamy Thangaraju, Noel Edwards, Nichola J. Conlon, Steven Woods, Vadivel Ganapathy, and David T. Thwaites

Epithelial Research Group, Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK (C.M.H.A., M.J., N.E., N.J.C., S.W., D.T.T.); and Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia (M.T., V.G.)
Running title: 5-Aminolevulinic Acid Transport via PAT1 and PepT1

Corresponding author: Prof. David T. Thwaites, Epithelial Research Group, Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. Telephone: +44 191 222 8559; Fax: +44 191 222 7424; E-mail: d.t.thwaites@ncl.ac.uk

Number of text pages: 28
Number of tables: 0
Number of figures: 6
Number of references: 40
Number of words in abstract: 250
Number of words in introduction: 597
Number of words in discussion: 1175

ABBREVIATIONS: ALA, 5-aminolevulinic acid; PpIX, protoporphyrin IX; PepT1, \( \text{H}^+ \)-coupled di/tripeptide transporter 1; PAT1, \( \text{H}^+ \)-coupled amino acid transporter 1; Gly-Sar, glycylsarcosine; MeAIB, \( \alpha \)-methylaminoisobutyric acid; D-Phe-Gln, D-phenylalanyl-L-glutamine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; OH-Trp, 5-hydroxy-L-tryptophan; AMBA, 4-aminomethylbenzoic acid; \( \beta \)-Ala, \( \beta \)-alanine; PepT2, \( \text{H}^+ \)-coupled di/tripeptide transporter 2; NHE3, Na\(^+\)/H\(^+\) exchanger NHE3; BCRP, Breast Cancer Resistance Protein.

Section: Metabolism, Transport and Pharmacogenomics
ABSTRACT

5-Aminolevulinic acid (ALA) is a pro-drug used in photodynamic therapy, fluorescent diagnosis and fluorescent-guided resection as it leads to accumulation of the photosensitizer protoporphyrin IX (PpIX) in tumor tissues. ALA has good oral bioavailability but high oral doses are required to obtain selective PpIX accumulation in colonic tumors as accumulation is also observed in normal gut mucosa. Structural similarities between ALA and GABA led us to test the hypothesis that the H⁺-coupled amino acid transporter PAT1 (SLC36A1) will contribute to luminal ALA uptake. Radiolabel uptake and electrophysiological measurements identified PAT1-mediated H⁺-coupled ALA symport following heterologous expression in Xenopus oocytes. The selectivity of the non-transported inhibitors 5-hydroxy-tryptophan and 4-aminobenzoic acid for, respectively, PAT1 and the di/tripeptide transporter PepT1 (SLC15A1) were examined. 5-Hydroxy-tryptophan selectively inhibited PAT1-mediated amino acid uptake across the brush-border membrane of the human intestinal (Caco-2) epithelium whereas 4-aminobenzoic acid selectively inhibited PepT1-mediated dipeptide uptake. The inhibitory effects of 5-hydroxy-tryptophan and 4-aminobenzoic acid were additive demonstrating that both PAT1 and PepT1 contribute to intestinal transport of ALA. This is the first demonstration of overlap in substrate specificity between these distinct transporters for amino acids and dipeptides. PAT1 and PepT1 expression was monitored by RT-PCR using paired samples of normal and cancer tissue from human colon. mRNA for both transporters was detected. PepT1 mRNA was increased 2.3 fold in cancer tissues. Thus, increased PepT1 expression in colonic cancer could contribute to the increased PpIX accumulation observed. Selective inhibition of PAT1 could enhance PpIX loading in tumor tissue relative to normal tissue.
Introduction

Photodynamic therapy of cancer involves the activation of a photosensitizer by light to induce localised cell death. The naturally-occurring heme precursor 5-aminolevulinic acid (ALA) is used as a pro-drug in photodynamic therapy of a wide variety of different solid tumors (Peng et al., 1997; Krammer and Plaetzer, 2008). ALA is converted by the heme biosynthesis pathway into the photosensitizer protoporphyrin IX (PpIX), which, when exposed to long wavelength light, releases highly reactive singlet oxygen (Kennedy and Pottier, 1992). Topical or systemic application of ALA leads to selective accumulation of PpIX within tumor cells which reduces non-specific tissue damage during photodynamic therapy (Kennedy and Pottier, 1992). This selectivity has also been exploited in diagnosis and fluorescent-guided resection of tumors (e.g. malignant glioma) where accumulated PpIX makes tumors fluoresce under illumination (Stummer et al., 2006). The molecular basis of the tumor-selective PpIX accumulation is not clear, although altered activity of enzymes in the heme biosynthesis pathway, which convert ALA to PpIX and PpIX to heme, has been suggested (Kennedy and Pottier, 1992; van Hillegersberg et al., 1992).

ALA is rapidly cleared from the body which reduces potential side-effects such as enduring cutaneous photosensitivity following treatment (Loh et al., 1993; van den Boogert et al., 1998). One of the key advantages of ALA-based therapy is its good oral bioavailability. In rats, oral ALA produces a plasma ALA level within one hour similar to that achieved by i.v. delivery of an equivalent dose (van den Boogert et al., 1998). Oral dosage with ALA is also used in photodynamic therapy of gastrointestinal tumors. However, relatively high doses of ALA are required to produce adequate PpIX tumor/normal mucosa ratios, due to the high background accumulation in normal epithelial cells (Loh et al., 1993; Regula et al., 1995; Peng et al., 1997).
One of the unanswered questions of ALA-based therapy is how the hydrophilic ALA is absorbed from the lumen of the gastrointestinal tract. There is convincing evidence that the intestinal H⁺-coupled di/tripeptide transporter PepT1 (SLC15A1) can transport ALA (Döring et al., 1998) and so may be involved in ALA transport across the intestinal epithelial brush-border membrane. However, the structure of ALA is also analogous to that of the neuroactive amino acid GABA suggesting that ALA may also interact with a GABA uptake system. To test this hypothesis, ALA transport by the H⁺-coupled amino acid transporter PAT1 (SLC36A1; Boll et al., 2002; Chen et al., 2003) was measured. PAT1 mediates uptake of GABA, other small neutral amino acids (e.g. proline, glycine, taurine) and a large number of related amino acid analogues across the apical membrane of intestinal epithelial cells (Thwaites et al., 1995; 2000; Anderson et al., 2004; Metzner et al., 2006; Thwaites and Anderson, 2007a). PAT1 can also transport therapeutic GABA analogues such as vigabatrin and gaboxadol (Abbot et al., 2006; Larsen et al., 2009) which may account for the excellent bioavailability of these drugs when given orally. PAT1 transport, like that of PepT1, is driven by the H⁺-electrochemical gradient that exists due to an area of low pH adjacent to the intestinal luminal surface called the acid microclimate (McEwan et al., 1988; Thwaites and Anderson, 2007b). Using a combination of heterologous expression in Xenopus laevis oocytes and endogenous expression in Caco-2 cell monolayers, we show that PAT1 is a novel pH-dependent, rheogenic H⁺/ALA transporter and that both PAT1 and PepT1 contribute to ALA uptake across the brush-border membrane of intestinal epithelial cells. We also consider the possibility that ALA transport may contribute to selective PpIX accumulation within tumor cells after observing increased expression of PepT1, but not PAT1, mRNA in colon cancer.
Methods

Materials. [14C]Glycylsarcosine (Gly-Sar; 56mCi/mmol), [3H]GABA (90Ci/mmol), [3H]glycine (16Ci/mmol) and [3H]L-methionine (73Ci/mmol) were from GE Healthcare (Little Chalfont, UK). [3H]5-Aminolevulinic acid hydrochloride (30Ci/mmol) and [3H]β-alanine (50Ci/mmol) were from American Radiolabeled Chemicals (Saint Louis, MO). [3H]L-Lysine (92-98.5Ci/mmol) and [14C]α-methylaminoisobutyric acid (MeAIB; 50.5 mCi/mmol) were from PerkinElmer (Beaconsfield, UK). [3H]L-Proline was from either PerkinElmer (75Ci/mmol) or GE Healthcare (43Ci/mmol). [3H]D-Phenylalanyl-L-glutamine (D-Phe-Gln; 17.4Ci/mmol) was from Cambridge Research Biochemicals (Stockton-on-Tees, UK). All other chemicals were from SigmaAldrich (Poole, UK) or VWR (Lutterworth, UK).

Expression in Xenopus laevis oocytes. Oocytes were isolated as described previously (Anderson et al., 2004). cRNA was synthesised by in vitro transcription either using the mMessage mMachine T7 kit (Ambion, Warrington, UK) (PAT1) or as described previously (Kennedy et al., 2002) (PepT1). Oocytes were injected with 50nl cRNA (1 mg/ml) or water (as a control) and maintained for at least 2 days before use, as described previously (Anderson et al. 2004).

Transport measurements in oocytes. Uptake of [3H]ALA, [3H]β-alanine or [14C]Gly-Sar (all 5 μCi/ml, 100μM) was measured at 22°C for 30-40min, essentially as described previously (Anderson et al., 2004). Briefly, oocytes were washed in Na+-free uptake solution (100mM choline chloride, 2mM KCl, 1mM CaCl2, 1mM MgCl2, 10mM HEPES adjusted to pH 7.4 with tris base) and then uptake measured at pH 5.5, 6.5 or 7.4. For pH 5.5, HEPES was replaced by MES. After uptake, oocytes were washed three times in ice-cold uptake buffer (without radiolabel), lysed in 10% SDS and radioactivity measured by scintillation counting.
Trans-stimulation of $[^3H]\beta$-alanine efflux from oocytes was determined following oocytes injection with 50nl $[^3H]\beta$-alanine (50mM, 0.1μCi/μl). Assuming an effective oocyte volume of 250nl (You et al., 1993) this would equate to an intracellular $\beta$-alanine concentration of approximately 8mM. After injection, oocytes were allowed to recover for 15min before washing and measurement of efflux in uptake solution (as above, pH 5.5) for 10min at 22°C. Efflux was measured in the presence and absence of potential trans-stimulating compounds (20mM). The amount of radioactivity effluxed into the uptake solution was then measured by scintillation counting.

**Two-electrode voltage-clamp.** Oocytes were clamped at -60mV whilst being superfused with Na$^+$-free pH 5.5 buffer in the presence or absence of various compounds (see figure legends for details). Current changes associated with H$^+$-coupled transport were measured using a Geneclamp 500 amplifier, Digidata 1200 (Axon Instruments) and pClamp software. To determine the current evoked by a substrate, the current measured over the last 15s of the exposure time was averaged. The baseline current (taken as the average current over the 15s before exposure to the substrate) was then subtracted. Current-voltage (I-V) relationships were determined by clamping membrane potential at -60mV then stepping sequentially between -100 and +80mV in 20mV steps (each for 200ms). I–V measurements made in the absence of a substrate were subtracted from those made when substrate-induced current flow reached steady-state.

**Uptake measurements in Caco-2 cell monolayers.** Caco-2 cells were grown as confluent monolayers of polarised cells on Transwell polycarbonate filters (Corning, Schiphol-Rijk, The Netherlands), as described previously (Thwaites et al., 1995). Prior to uptake, Caco-2 cell monolayers were washed (4 x 500ml) and bathed in Na$^+$-free Krebs’ solution (137mM choline chloride, 5.4mM KCl, 1mM MgSO$_4$, 0.34mM KH$_2$PO$_4$, 2.8mM CaCl$_2$, 10mM glucose, 10mM HEPES adjusted to pH 7.4 with tris base). Apical uptake of
various radiolabelled amino acids (0.8μCi/ml, all 10μM except [14C]MeAIB which was 26μM), [3H]ALA, [3H]β-alanine or [3H]d-Phe-Gln (all 0.5μCi/ml, 100μM) was measured over 5-15min at 37°C, apical pH 7.4 or pH 5.5 (HEPES substituted with MES) and basolateral pH 7.4. Monolayers were washed immediately in ice-cold solution (3 x 500ml) and removed from the plastic inserts to allow radioactivity to be measured by scintillation counting.

**Tissue collection.** Eighteen adult patients with colorectal cancer were included after obtaining their informed consent and Medical College of Georgia institutional review board's approval (Gupta et al., 2006). Samples 1-6 were from patients GM1-GM6, sample 7 from GM18, samples 8-16 from GM 24-32, sample 17 from GM34, and sample 18 from GM36 (see Gupta et al., 2006, for patient details). Total RNA from mucosal samples (paired normal and cancer samples) was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer's instructions.

**Reverse transcriptase-polymerase chain reaction (RT-PCR).** RNA was reversed transcribed using the GeneAmp PCR system (Applied Biosystems, Branchburg, NJ). PCR was carried out using the following primers: PepT1, forward GGCTGGACTGGGCTAAAGAGAAATACGATG, reverse GTTGGCCCTGCTTGAAGTCGTCAGTTAC; PAT1, forward CCACCAATAACTGCCACAACAATGAGACGG, reverse TGCGCACAAACAGGTCCACCACTAACTCAC. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a universal control. The levels of PAT1 and PepT1 were quantified by densitometry scanning and normalized to the intensities of the corresponding GAPDH bands.

**Data Analyses.** Data are expressed as mean ± SEM. For all radiolabel transport measurements, experiments were repeated two to three times using at least 9-10 oocytes per condition within each replicate, or 5-6 Caco-2 cell monolayers per condition within each
replicate. For two-electrode voltage-clamp experiments, measurements were made on 4-5 individual oocytes from at least two frogs. Statistical comparisons of mean values were made using unpaired, two-tailed Student’s t-test or one-way ANOVA as appropriate. Significance was assumed if p<0.05. Kinetic analyses to determine $K_m$ and $V_{max}$ values were carried out by fitting Michaelis-Menten kinetics (describing a single saturable transport system) and confirmed by linear regression analysis using the Eadie-Hofstee equation. $K_m$ is the Michaelis constant, the concentration of substrate necessary for half-maximal transport. $IC_{50}$ values (concentration of inhibitor necessary to produce 50% inhibition) were estimated from semi-logarithmic plots of the inhibitor concentrations versus substrate uptake relative to the uninhibited control. Non-linear and linear regression were fitted using Prism 4 (GraphPad Software Inc., San Diego, CA).
Results

**PAT1 is a novel H⁺-coupled ALA transporter.** pH-dependent, H⁺-coupled ALA uptake was measured in PAT1-expressing oocytes (Fig. 1). At pH 5.5 and 6.5 but not pH 7.4 there was significantly greater [³H]ALA uptake in PAT1-expressing oocytes than control (water-injected) oocytes (Fig. 1A). ALA uptake at pH 5.5 was inhibited by the PAT1 substrates β-alanine and GABA (both 20mM, Fig. 1B). To characterize PAT1-mediated ALA uptake, rheogenic transport (consistent with H⁺/zwitterion symport) was measured as inward positive charge movement by the two-electrode voltage-clamp technique (Fig. 1 C, D). ALA caused inward current in oocytes heterologously expressing PAT1 but not in control oocytes (Fig. 1D). The current induced by ALA was consistently smaller than for GABA and β-alanine (Fig. 1C, D). The affinity of PAT1 for ALA (Kₘ = 10.4 ± 5.6mM; shown in Fig. 1F) was also lower than for GABA (Kₘ = 1.1 ± 0.5mM, data not shown).

**Transport of ALA via PepT1.** A previous study by Daniel and colleagues identified that the intestinal di/tripeptide transporter PepT1 could transport ALA (Döring et al., 1998). To compare ALA transport via PepT1 and PAT1, PepT1 was expressed in oocytes. At pH 5.5, significantly more [³H]ALA uptake was measured in oocytes injected with PepT1 cRNA compared to water-injected controls (uptake being 43.5 ± 3.8 and 4.6 ± 0.4 pmol.oocyte⁻¹.[40min]⁻¹, p<0.001, in PepT1-expressing and control oocytes, respectively). Like PAT1, PepT1 is a H⁺-coupled transporter and rheogenic transport can be measured by the two-electrode voltage-clamp technique. ALA induced similar levels of current in PepT1-expressing oocytes as the prototypical substrate Gly-Sar (Fig. 1E) and the affinity of PepT1 for ALA (Kₘ = 1.6 ± 0.9mM, Fig. 1F) was comparable to that reported previously for Gly-Sar (Kₘ = 1.9mM; Fei et al., 1994).
Characterisation of non-transported inhibitors of PAT1 and PepT1. Figure 1 shows clearly that, despite their distinct substrate specificities, both the amino acid transporter PAT1 and the di/tripeptide PepT1 can transport ALA in a pH-dependent, H+-coupled manner. Previous studies have identified both PAT1 and PepT1 at the apical membrane of the small intestinal epithelium (and the model cell line Caco-2) (Walker et al., 1998; Chen et al., 2003) where they may both play important roles in nutrient and drug absorption (Rubio-Aliaga and Daniel, 2002; Thwaites and Anderson, 2007a). To identify whether both PAT1 and PepT1 play roles in ALA uptake across the brush-border membrane of the small intestinal epithelium it was necessary to use non-transported inhibitors of each transporter. Such inhibitors will mitigate any potential interaction caused by changes in pH, associated with the saturating concentrations of transported substrates normally used in competition experiments.

5-Hydroxy-L-tryptophan (OH-Trp) has been proposed as a non-transported inhibitor of PAT1 (Metzner et al., 2005). Uptake of [³H]β-alanine by PAT1 expressed in oocytes was inhibited in a concentration-dependent manner by OH-Trp (IC₅₀ = 1.2 ± 0.3mM; Fig. 2A). OH-Trp (20mM) caused no current change in PAT1 oocytes but could inhibit current induced by β-alanine (2mM) by 89% (p<0.001; Fig. 2B). This observation suggests that OH-Trp is either a non-transported inhibitor or possibly a substrate transported in a non-rheogenic manner. Consistent with being a non-transported inhibitor, extracellular OH-Trp (20mM) was unable to trans-stimulate PAT1-specific efflux of β-alanine from oocytes (p>0.05) whereas the PAT1 substrates GABA and proline (20mM) caused significant trans-stimulation (p<0.001, Fig. 2C). As a control, the amino acid glutamate (20mM), which is not a substrate for PAT1 (Thwaites et al., 1995), was included and did not cause trans-stimulation. PAT1-mediated [³H]ALA uptake was reduced by 96% by OH-Trp (20mM; Fig. 2D). Similarly current induced by ALA (10mM) was reduced to 11.4 ± 1.8% (p<0.001) by OH-Trp (20mM).
A non-transported inhibitor of PepT1 was discovered due to its ability to inhibit dipeptide uptake but inability to cause trans-stimulation (Meredith et al., 1998). 4-aminomethylbenzoic acid (AMBA) inhibited [14C]Gly-Sar uptake into PepT1-expressing oocytes (IC50 = 4.4 ± 1.5mM; Fig. 3A). AMBA (30mM) induced no current in PepT1-expressing oocytes suggesting that PepT1 does not transport AMBA (Fig. 3B). At 30mM, AMBA significantly inhibited (p<0.001) current caused by 1mM Gly-Sar (Fig. 3B, C). Similarly, 30mM AMBA inhibited PepT1-mediated [3H]ALA uptake by 82% (Fig. 3D). The dipeptide Val-Val (20mM) completely inhibited PepT1-mediated [3H]ALA uptake (Fig. 3D). Importantly, the PAT1 inhibitor OH-Trp had no effect (p>0.05) on PepT1-mediated [3H]ALA uptake (Fig. 3D) and the PepT1 inhibitor AMBA had no effect (p>0.05) on PAT1-mediated [3H]ALA uptake (Fig. 2D) making these tools suitable for investigation of the contribution of PAT1 and PepT1 to ALA uptake across the luminal membrane of the intestinal epithelium.

**Both PAT1 and PepT1 mediate ALA uptake at the intestinal brush-border membrane.** Caco-2 cell monolayers grown on permeable supports are frequently used as a model of the small intestinal epithelium. The interaction of ALA with amino acid transport at the intestinal brush-border membrane was assessed (Fig. 4A). Uptake of the PAT1 substrates β-alanine, GABA, glycine, l-proline and MeAIB were all significantly reduced by ALA (10mM; p<0.01; Fig. 4A). In contrast, the uptake of amino acids not transported by PAT1, such as lysine and methionine (Thwaites et al., 1995), were unchanged in the presence of ALA (p>0.05). The inhibition of [3H]β-alanine uptake by ALA was concentration-dependent (Fig. 4B). The IC50 for ALA inhibition of apical amino acid uptake in Caco-2 cells (7.1 ± 0.9mM) was close to the affinity constant estimated by electrophysiology in PAT1-expressing oocytes (Fig. 1).

[3H]ALA uptake was measured across the apical membrane of Caco-2 cell monolayers. [3H]ALA uptake was significantly greater in the presence of a pH gradient...
consistent with both PAT1- and PepT1-mediated transport (uptake being 9 ± 1 and 47 ± 2 pmol.cm⁻².min⁻¹ at apical pH 7.4 and 5.5, respectively; p<0.001). [³H]ALA uptake was inhibited by either AMBA (30mM) or OH-Trp (20mM) when tested individually (Fig. 5A). Inclusion of both OH-Trp and AMBA lead to significantly greater (additive) inhibition of apical [³H]ALA uptake than either compound caused individually (p<0.001; Fig. 5A). The non-transported PAT1 inhibitor, OH-Trp (20mM) reduced uptake of the PAT1 substrate [³H]β-alanine to a similar degree as that observed with unlabelled β-alanine (30mM) (Fig. 5B) but had no effect on uptake of the PepT1 substrate [³H]D-Phe-Gln (Fig. 5C). The non-transported PepT1 inhibitor AMBA (30mM) inhibited uptake of [³H]D-Phe-Gln but to a lesser extent than the dipeptide Val-Val (30mM) (Fig. 5C) and had no effect on uptake of [³H]β-alanine (Fig. 5B). These data confirm that the two inhibitors, OH-Trp and AMBA, are selective for PAT1 and PepT1, respectively, in a cell system where both transporters are co-expressed in the same cell membrane. Therefore, these data demonstrate that both PAT1 and PepT1 contribute to ALA transport across the brush-border membrane of intestinal epithelial cells (Fig. 5A). It should be noted that AMBA (30mM) does not completely inhibit dipeptide uptake (Fig. 5C). Therefore, the degree of inhibition by AMBA observed in Fig. 5A will underestimate the PepT1 contribution to [³H]ALA uptake. If AMBA were to inhibit PepT1-mediated [³H]ALA uptake with a similar efficiency as observed with Val-Val on [³H]D-Phe-Gln, then we estimate that the [³H]ALA uptake following inhibition of PepT1 (in the studies reported in Fig. 5A) would be reduced to approximately 42 pmol.cm⁻².min⁻¹. This level of [³H]ALA uptake is similar to that measured following inhibition of PAT1 (as observed in the presence of OH-Trp) which was 49 pmol.cm⁻².min⁻¹ (Fig. 5A). Competition experiments using substrates rather than non-transported inhibitors are complicated by the effects of substrate-induced pH changes. Therefore, although AMBA is only a low affinity inhibitor, it
has been a useful experimental tool in this investigation, as it negates potential non-specific effects on driving force.

**Expression of PAT1 and PepT1 in colon cancer.** For increased conversion of oral ALA to PpIX to occur in tumors, accumulation of ALA within tumor cells is firstly required. Therefore, expression of PAT1 and PepT1 in colon cancer and normal tissue was investigated (Fig. 6). Eighteen paired biopsy samples from patients with colorectal cancer were screened for PAT1 and PepT1 expression at the mRNA level (Fig. 6A). The relative expression of PAT1 was not significantly different between normal and tumor tissue (Fig. 6B) which may indicate that PAT1 contributes to ALA accumulation in both normal and tumor intestinal mucosa. However, PepT1 expression was increased in all eighteen tumor samples, with an average increase of $2.3 \pm 0.1$ fold (Fig. 6B). Therefore, it is conceivable that increased PepT1 expression could contribute to increased ALA, and subsequent PpIX, accumulation in colon cancer and other tumors.
Discussion

The H⁺-coupled amino acid transporter PAT1 acts as a high capacity, absorptive route for small neutral amino acids, such as GABA, and many orally-active analogues across the brush-border membrane of the small intestine (Thwaites et al., 2000; Chen et al., 2003; Anderson et al., 2004; Abbot et al., 2006; Metzner et al., 2006; Thwaites and Anderson, 2007a; Larsen et al., 2009). PAT1 can also be considered a novel intestinal transporter of the heme precursor ALA which is used extensively in photodynamic therapy. PAT1 has a relatively low affinity for ALA (K_m 10.4mM; Fig. 1A) compared with GABA (K_m 1.1mM), but the affinity is within the range of that for other naturally-occurring PAT1 substrates such as glycine, L-proline, L-alanine and taurine (K_m ~2-10mM; Thwaites et al., 1995; Boll et al., 2002; Metzner et al., 2006; Anderson et al., 2009).

During photodynamic therapy, ALA is typically given orally in the range 10-60mg/kg body weight, in small amounts of fluid, either as a bolus or in fractionated doses. The low molecular weight of ALA (mol. wt. 167) makes it conceivable that concentrations around the K_m of PAT1 are achieved in the intestinal lumen.

The data presented here show that ALA transport across the brush-border membrane of the human small intestinal epithelium is via both PAT1 and the H⁺-coupled di/tripeptide transporter PepT1 (Fig. 5). Understanding the mechanisms by which ALA is transported across the brush-border membrane is essential when considering the potential for patient variability either through polymorphisms, drug-drug interactions or pathophysiological regulation of intestinal function. Both PAT1 and PepT1 are regulated by a range of dietary, (patho)physiological and neurohormonal pathways (Anderson et al., 2003; Daniel, 2004; Thwaites and Anderson, 2007a) which in turn may alter the efficacy of photodynamic therapy.
As ALA readily appears in the plasma after oral dosage (van den Boogert et al., 1998), it must also be transported, intact, across the basolateral membrane of the small intestinal epithelium. There is some evidence that this may be via the, as yet unidentified, basolateral di/tripeptide transporter described in cell cultures (Irie et al., 2001). In other cells, ALA transport may be via either amino acid or peptide transporters. A common transport system for ALA, and the structurally analogous GABA, was first shown in Saccharomyces cerevisiae (Bermúdez Moretti et al., 1995). Around the same time, studies in bacteria identified ALA transport via a dipeptide permease (Elliott, 1993). Daniel and colleagues (Döring et al., 1998) were first to show that ALA is an excellent substrate not only for PepT1 but also for non-intestinal PepT2 (SLC15A2). Subsequently, PepT1 was shown to mediate ALA transport in cholangiocytes where its affinity for the transporter (K_m 2.1mM) is similar to that for PepT1 in this study (Fig. 2; Neumann and Brandsch, 2003). Studies using knockout mice demonstrate that PepT2 plays a key role not only in ALA reabsorption in the kidney but also in limiting ALA neurotoxicity by removal of ALA from the cerebrospinal fluid (Hu et al., 2007). In certain cell lines, ALA transport has been attributed to members of the SLC6 family of Na^+ - and Cl^-coupled amino acid transporters, particularly the high-affinity GAT transporters (Rud et al., 2000; Bermúdez Moretti et al., 2002). Therefore, ALA transport will vary depending upon the complement of amino acid and dipeptide transporters expressed in each cell type. The work presented here is the first study to demonstrate overlapping substrate specificity of distinct transporters for dipeptides and amino acids co-expressed in the same functional compartment of a cell.

Substantial transport of ALA into intestinal epithelial cells after oral ALA is evident by the accumulation of PpIX within normal intestinal mucosal tissue measured by fluorescent imaging (Loh et al., 1993; Regula et al., 1995). However, the high background accumulation of PpIX in gastrointestinal epithelia is also a limiting factor in achieving sufficient PpIX.
tumor/normal mucosa ratios necessary for effective photodynamic therapy of gastrointestinal tumors. Thus, much higher doses of ALA are required (40-60mg/kg body weight) to achieve reasonable tumor selectivity in colon cancer compared to the oral doses used successfully in the detection of other tumors such as malignant glioma (10-20mg/kg body weight) (Loh et al., 1993; Regula et al., 1995, Peng et al., 1997; Stummer et al., 2006). The variation in accumulation of PpIX after ALA dosage, both between normal and tumor tissue and between different types of tumors, is still a matter of debate and is likely to be multi-factorial. Clearly, the first step required for in situ PpIX synthesis is the effective transport of ALA into the tumor cell. Therefore, increased ALA transport capacity may facilitate PpIX accumulation in combination with downstream effects such as the reduced ferrochelatase activity (which converts PpIX to heme) reported in some tumors (van Hillegersberg et al., 1992). Figure 6 shows that both PepT1 and PAT1 are expressed in human colon cancer. The consistent increase in PepT1 expression in all tumor samples investigated is the first evidence that an ALA uptake mechanism may be altered in colon cancer. Upregulation of PepT1 in cancer may not be restricted to colonic tumors. [11C]Gly-Sar has been found to accumulate in mouse tumor xenografts originating from human pancreatic, prostate and gastric cancer cells (Mitsuoka et al., 2008). As well as influencing photodynamic therapy, increased PepT1 expression in cancer would be of potential therapeutic advantage in the delivery of the anticancer PepT1 substrate bestatin (Rubio-Aliaga and Daniel, 2002). It is tempting to speculate that the aberrant expression of H+-coupled transporters could provide a selective advantage for cancer cells by providing nutrient uptake pathways which can exploit the acid extracellular milieu associated with many solid tumors (Gerweck and Seetharaman, 1996). Thus, selective inhibitors for such transporters could be a means to limit tumor nutritional supply. Further investigation is required to determine whether PepT1 functional capacity is increased in colon cancer.
Interestingly, previous work has demonstrated that expression of the PpIX efflux pump BCRP (Breast Cancer Resistance Protein, ABCG2) is down-regulated in colon cancer (Gupta et al., 2006). Thus, a combination of increased PepT1 expression and decreased BCRP expression could produce a selective increase in PpIX accumulation in cancer tissues. In addition, we demonstrate that co-administration of non-transported inhibitors of either PAT1 or PepT1 result in selective reduction of ALA uptake in small intestinal epithelial cells (without any inhibition of the second transporter) (Figs. 2, 3, and 5). These observations reveal a potential method for improvement in selective ALA loading in colon cancer cells compared to normal mucosa. Co-administration of a selective non-transported PAT1 inhibitor with ALA, as demonstrated in vitro here using OH-Trp, could reduce background PpIX accumulation in normal mucosa. The relatively high expression of PepT1 in cancerous tissue would then favour ALA uptake into cancer cells. Further experimentation is required to test these possibilities.

In conclusion, this study shows that PAT1 is a novel transporter for ALA and that both PAT1 and PepT1 will contribute to the absorption of oral ALA across the brush-border membrane of the human small intestinal epithelium. The role of H+-coupled nutrient transporters such as PAT1 and PepT1 in cancer biology and anti-cancer therapeutic regimes merits further investigation.
Acknowledgements

We thank Mrs. Lisa Burdis for excellent technical assistance.
References


Anderson CMH, Mendoza ME, Kennedy DJ, Raldua D, and Thwaites DT (2003) Inhibition of intestinal dipeptide transport by the neuropeptide VIP is an anti-absorptive effect via the VPAC1 receptor in a human enterocyte-like cell line (Caco-2). Br J Pharmacol 138: 564-573.


transport of the dipeptide glycylsarcosine is dependent on functional Na⁺/H⁺ exchange activity. *Pflügers Archiv* **445**: 139-146.


Footnotes

This work was supported by the Wellcome Trust [Grant 078640/Z/05/Z]. MJ and NE hold Biotechnology and Biological Sciences Research Council funded PhD studentships. NJC holds a Medical Research Council funded PhD studentship.

Part of this work was presented at the international conference Digestive Diseases Week 2009 in Chicago, IL (2009 May 31 – June 3) and published in abstract form [Anderson CMH, Jevons, M, and Thwaites DT (2009) Luminal Uptake of the Photodynamic Therapy Agent 5-Aminolevulinic Acid via the Proton-Coupled Amino Acid Transporter PAT1 (SLC36A1) in Human Intestinal Epithelial Cells. Gastroenterology 136(5): A-570].

Address correspondence to: Prof. David T. Thwaites, Epithelial Research Group, Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. E-mail: d.t.thwaites@ncl.ac.uk
Legends for Figures

**Fig. 1.** PAT1 and PepT1 are both H⁺-coupled ALA transporters. (A) [³H]ALA uptake (100μM) into PAT1-expressing oocytes was pH-dependent. *** p<0.001, ** p<0.01, NS p>0.05, all vs. water-injected (control) oocytes. (B) [³H]ALA uptake at pH 5.5 (control) was inhibited by the PAT1 substrates β-alanine and GABA (both 20mM). *** p<0.001 vs. control. (C) Two-electrode voltage-clamp was used to measure PAT1-mediated H⁺-coupled transport. Superfusion of GABA, β-alanine or ALA (all 20mM) in pH 5.5 buffer for 2min caused inward current in PAT1-expressing oocytes. (D) Current-voltage (I/V) relationship for GABA, β-alanine and ALA (all 10mM) in PAT1-expressing oocytes. ALA caused no current in water-injected control oocytes. (E) ALA and Gly-Sar (20mM) both induced inward current in PepT1-expressing oocytes. (F) Concentration-dependent current induced by ALA in PAT1- or PepT1-expressing oocytes relative to appropriate control (20mM GABA for PAT1, 20mM Gly-Sar for PepT1). Data are fitted with Michaelis-Menten kinetics. Insert: Eadie-Hofstee plot [current (V) vs. current/ALA concentration (V/S)].

**Fig. 2.** OH-Trp is a non-transported inhibitor of PAT1. (A) Concentration-dependent inhibition of PAT1-mediated [³H]β-alanine (100μM) uptake (40min, pH 5.5) by OH-Trp (0.1-30mM). Data represent uptake after subtraction of uptake into water-injected control oocytes measured under identical conditions. (B) OH-Trp (20mM) induced no current in PAT1-expressing oocytes but significantly reduced the current associated with β-alanine (2mM). *** p<0.001 vs. β-alanine. (C) Extracellular OH-Trp (20mM) did not trans-stimulate PAT1-specific [³H]β-alanine efflux whereas the PAT1 substrates GABA and proline (both 20mM) caused significant trans-stimulation. Glutamate (20mM), which is not a PAT1 substrate, did not trans-stimulate PAT1-specific [³H]β-alanine efflux. *** p<0.001, NS p>0.05, vs. control.
(D) Inhibition of PAT1-mediated $[^3]H$ALA (100μM) uptake (pH 5.5) by OH-Trp (20mM) but not by the PepT1 inhibitor AMBA (4-aminomethylbenzoic acid; 30mM). *** p<0.001, NS p>0.05, vs. control.

Fig. 3. AMBA is a non-transported inhibitor of PepT1. (A) Concentration-dependent inhibition of $[^{14}]$Gly-Sar (100μM) uptake via PepT1 by the inhibitor AMBA (0.1-40mM). Data represent uptake after subtraction of uptake into water-injected control oocytes measured under identical conditions. (B) and (C) AMBA (30mM) inhibited current induced by Gly-Sar (1mM) in PepT1-expressing oocytes but did not induce any current when superfused alone. *** p<0.001 vs. Gly-Sar. (D) AMBA (30mM) and the dipeptide Val-Val (20mM) both inhibited PepT1-mediated $[^3]H$ALA (100μM) uptake (pH 5.5) whereas the PAT1 inhibitor OH-Trp (20mM) had no effect. *** p<0.001, NS p>0.05, vs. control.

Fig. 4. ALA inhibition of PAT1-mediated amino acid uptake at the apical membrane of the human intestinal cell line Caco-2. The cells were grown as confluent monolayers of polarized cells on Transwell polycarbonate filters. (A) Apical uptake of the PAT1 substrates $[^3]H$β-alanine (10μM), $[^3]H$GABA (10μM), $[^{14}]$MeAIB (26μM), $[^3]H$glycine (10μM), $[^3]H$proline (10μM) and the non-substrates $[^3]H$lysine (10μM) and $[^3]H$methionine (10μM) measured in the presence and absence of apical ALA (10mM). Uptake was measured at apical pH 5.5, basolateral pH 7.4. *** p<0.001, ** p<0.01, NS p>0.05, all vs. control. (B) Concentration-dependent inhibition of $[^3]H$β-alanine (100μM) uptake measured at apical pH 5.5, basolateral pH 7.4 by unlabelled ALA or β-alanine.

Fig. 5. Both PAT1 and PepT1 mediate ALA uptake across the intestinal brush-border membrane. (A) Apical uptake of $[^3]H$ALA (100μM) was measured at apical pH 5.5,
basolateral pH 7.4, in the presence and absence of excess ALA (20mM), the PAT1 inhibitor OH-Trp (20mM) and/or the PepT1 inhibitor AMBA (30mM). *** p<0.001 vs. control; ††† p<0.001 vs. either +AMBA or +OH-Trp. (B) Apical uptake of the PAT1 substrate [³H]β-alanine (100μM) in the presence of the PAT1 inhibitor OH-Trp (20mM), the PepT1 inhibitor AMBA (30mM), or unlabelled β-alanine (30mM). *** p<0.001, NS p>0.05, vs. control. (C) Apical uptake of the PepT1 substrate [³H]D-Phe-Gln (100μM) in the presence of the PAT1 inhibitor OH-Trp (20mM), the PepT1 inhibitor AMBA (30mM), or the dipeptide Val-Val (30mM). *** p<0.001, ** p<0.01, NS p>0.05, vs. control.

**Fig. 6.** PepT1 expression is increased in colon cancer. (A) Expression of PepT1 and PAT1 in normal colon (N) and paired colon tumor (T) tissues from 18 patients (see methods) assessed by RT-PCR and compared to GAPDH as a control. (B) Semi-quantitative analysis of expression of PepT1 and PAT1 in normal and tumor tissues shown in (A) ratioed to GAPDH expression. *** p<0.001, NS p>0.05.
Figure 2

(A) PAT1-mediated [3H]β-alanine uptake (% control) as a function of 
log [OH-Trp] (M).

(B) Graph showing currents in response to different amino acids. 

(C) Bar graph showing [3H]β-alanine efflux from PAT1-expressing oocytes. 

(D) Bar graph showing [3H]ALA uptake in oocytes.
Figure 3

A

JPET Fast Forward. Published on September 29, 2009 as DOI: 10.1124/jpet.109.159822
This article has not been copyedited and formatted. The final version may differ from this version.

B

C

D

Gly-Sar AMBA Gly-Sar

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)

Gly-Sar AMBA + AMBA

Current (nA)
Figure 4

A

![Graph showing amino acid uptake](image)

B

![Graph showing [3H]β-Alanine uptake](image)
Figure 5

A

\[ \text{[^3]HALA uptake (pmol.cm}^{-2}.\text{min}^{-1}) \]

Control + OH-Trp + AMBA + OH-Trp + ALA + AMBA

B

\[ \text{[^3]H-\text{Alanine uptake (% control)}} \]

Control + OH-Trp + AMBA + \( \beta \)-Ala

C

\[ \text{[^3]H-Phe-Gln uptake (% control)}} \]

Control + OH-Trp + AMBA + Val-Val

*** NS ** ** **